Saint (neurostimulator for treating depression)

2023: Start implanting neurostimulators instead of antidepressants

On July 20, 2023, Magnus Medical, a manufacturer of medical equipment and developer of brain stimulation technology for the treatment of neuropsychiatric disorders, introduced Saint's system for the therapy of major depressive disorder (MDD).

It is noted that MDD is one of the most severe forms of depression. This mental state causes a constantly poor or depressed mood and a loss of interest in those activities that once brought joy. MDD is caused by various factors, including genetic predisposition, stress, and biochemical processes. Such depression can last months or even years. According to the National Institute, in health care 2020, approximately 21 million American adults faced at least one episode of MDD - this makes up 8.4% of the adult population. USA

Patients began to be implanted with neurostimulators instead of antidepressants

The Magnus Saint system uses structural and functional magnetic resonance imaging to form a special algorithm that determines the optimal brain region for targeted neurostimulation. The platform provides personalized, non-invasive therapy targeting those patients who have not been helped by traditional therapies, including antidepressant medication.

The treatment program provides 10 sessions per day lasting 10 minutes with 50-minute breaks. The course is designed for five days. By comparison, conventional treatment regimens for patients with MDD stretch for several weeks and even months.

The results of the randomized controlled trial were extremely promising - 79% of participants experienced relief from severe depression after treatment through Saint neurostimulation, said Brandon Bentzley, MD, co-founder and chief scientific officer of Magnus.[1]

Notes